Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $96.1. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | JNK | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $98.19 |
52-Week Low | $0.53 | $94.66 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
JNK trades at $95.76, down 0.18% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while technical support sits near $95.
The outlook for JNK is clouded by potential Fed rate hikes and bond market volatility. High-yield bond ETFs face headwinds from rising yields, though demand for yield remains strong. Risks include interest rate sensitivity and economic slowdowns, while institutional flows indicate mixed confidence in fixed income assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
